- Home
- GHRS vs TRTX Comparison
GHRS vs TRTX Comparison
Compare GHRS & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- TRTX
- Stock Information
- Founded
- GHRS 2018
- TRTX 2014
- Country
- GHRS Ireland
- TRTX United States
- Employees
- GHRS N/A
- TRTX N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- TRTX Real Estate Investment Trusts
- Sector
- GHRS Health Care
- TRTX Real Estate
- Exchange
- GHRS Nasdaq
- TRTX Nasdaq
- Market Cap
- GHRS 868.7M
- TRTX 695.8M
- IPO Year
- GHRS 2021
- TRTX 2017
- Fundamental
- Price
- GHRS $11.06
- TRTX $8.02
- Analyst Decision
- GHRS Strong Buy
- TRTX Strong Buy
- Analyst Count
- GHRS 7
- TRTX 5
- Target Price
- GHRS $30.86
- TRTX $9.40
- AVG Volume (30 Days)
- GHRS 257.0K
- TRTX 826.4K
- Earning Date
- GHRS 05-02-2025
- TRTX 04-29-2025
- Dividend Yield
- GHRS N/A
- TRTX 11.97%
- EPS Growth
- GHRS N/A
- TRTX N/A
- EPS
- GHRS N/A
- TRTX 0.75
- Revenue
- GHRS N/A
- TRTX $148,968,000.00
- Revenue This Year
- GHRS N/A
- TRTX N/A
- Revenue Next Year
- GHRS N/A
- TRTX N/A
- P/E Ratio
- GHRS N/A
- TRTX $10.73
- Revenue Growth
- GHRS N/A
- TRTX N/A
- 52 Week Low
- GHRS $6.00
- TRTX $6.99
- 52 Week High
- GHRS $20.50
- TRTX $9.66
- Technical
- Relative Strength Index (RSI)
- GHRS 45.98
- TRTX 30.57
- Support Level
- GHRS $10.20
- TRTX $8.43
- Resistance Level
- GHRS $13.21
- TRTX $8.62
- Average True Range (ATR)
- GHRS 0.90
- TRTX 0.16
- MACD
- GHRS 0.07
- TRTX -0.04
- Stochastic Oscillator
- GHRS 28.56
- TRTX 3.17
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.